Alto Neuroscience (ANRO) Stock Price

Alto Neuroscience Price

NYSE·CLOSED
24.47
​
Market closed

Analysts set a median price target of 36.00 USD, implying 47.1% above the current price. Of 17 analysts, 15 rate the stock a buy — an overall Buy consensus.

Alto Neuroscience stock price

Access this data via the Eulerpool API

Alto Neuroscience business model & stock analysis

Alto Neuroscience Inc is a US-based company operating in industry. The company is headquartered in Los Altos, California. The company went IPO on 2024-02-02. Alto Neuroscience, Inc. is a clinical-stage biopharmaceutical company. The firm is focused on redefining psychiatry by leveraging individuals’ neurobiology to develop personalized and effective treatment options. Through insights derived from the Company’s scalable and proprietary Precision Psychiatry Platform, which applies rigorous data science and robust analytics to data gathered by neurocognitive assessments, electroencephalography, and wearable devices, the Company aims to discover brain-based biomarkers to better identify which patients are more likely to respond to its novel product candidates. Its pipeline consists of five clinical-stage assets, such as ALTO-100, ALTO-202, ALTO-300, ALTO-101, and ALTO-203, which target depressive disorder and schizophrenia populations as identified by independent brain-based biomarkers. Its pipeline also includes novel drug candidates in depression, post-traumatic stress disorder (PTSD), and other mental health conditions.

Frequently asked questions about Alto Neuroscience

Analysts currently set an average price target of 37.40 USD for the Alto Neuroscience stock (median: 36.00 USD), implying +52.9 % versus the latest price. The consensus is based on 17 analyst ratings.

17 analysts currently rate the Alto Neuroscience stock: 15 recommend buying, 2 holding and 0 selling.

Converted at the current exchange rate, the Alto Neuroscience share trades at 21.83 EUR (24.47 USD).

The revenue cannot currently be calculated for Alto Neuroscience.

The expected profit of Alto Neuroscience is -86.51 M USD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Alto Neuroscience is currently -9.03. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Alto Neuroscience stock.

The P/S cannot be calculated for Alto Neuroscience currently.

The Eulerpool Quality Score for Alto Neuroscience is 2/10.

The ISIN of Alto Neuroscience is US02157Q1094. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of Alto Neuroscience is ANRO. The ticker symbol is used to trade Alto Neuroscience shares on the stock exchange.

Fair ValueTerminal
23.73 USD
Over-/UndervaluationTerminal
Fairly valued
Sector
—
Industry
Other
Number of shares
Employees
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Currency
USD
Initial public offering
Feb 2, 2024
ISIN
US02157Q1094
Cusip
02157Q109
Market capitalization
760.13 M USDSmall Cap
52-Week Range
PEG
0.41
P/E ratio
P/Ee 2026
-9.03
P/Ee 2028
-8.23
P/Ee 2029
-8.38
P/Ee 2030
-38.55
P/S
P/Se
—
EV/EBIT
—
P/B Ratio
5.03
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
-37.17 %
Last updated Oct 11, 2026, 4:50 PM

Alto Neuroscience Peer Group